Literature DB >> 19665066

A MLH1 polymorphism that increases cancer risk is associated with better outcome in sporadic colorectal cancer.

Nargisse Nejda1, Daniel Iglesias, Mariano Moreno Azcoita, Vicente Medina Arana, Juan J González-Aguilera, Antonia M Fernández-Peralta.   

Abstract

Germline mutations or the malfunctioning of postreplicative mismatch repair genes (MMR) are responsible of hereditary nonpolyposis colorectal cancer (HNPCC), and are also implied in some sporadic colorectal cancer (CRC) forms without any familial history of this disease. Besides germinal mutations and methylation, single-nucleotide polymorphisms (SNP) can predispose to nonfamilial CRC with low to moderate penetrance. In this case-control study, we analyzed three MLH1 single-nucleotide polymorphisms (exon 5: 415G-->C, rs28930073; exon 8: 655A-->G, rs1799977 and exon 16: 1852-1853AA-->GC) in 140 sporadic colorectal cancer cases and 125 healthy individuals to evaluate the relationship among CRC risk and clinicopathologic and genetic characteristics of the tumors. In our study, no 415G-->C variant carrier was found among all analyzed samples. The 1852-1853AA-->GC is a rare variant detected in heterozygoses in five controls and one case. In relation to the more frequent 655A-->G polymorphism, association analyses revealed that G carriers (AG or GG genotype) displayed a higher risk of CRC compared with AA homozygous [odds ratio (OR) AG=2.55, 95% confidence interval (CI)=1.48-4.39; P=0.01 and OR GG=2.48, 95% CI=1.20-5.11; P=0.01, respectively]. G-carrier males showed high CRC risk compared with homozygous AA wild-type individuals (OR: AG=3.05; 95% CI=1.49-6.26, P=0.002; OR: GG=3.60; 95% CI=1.29-10.03). Nevertheless, patients carrying the G allele displayed a better outcome than wild-type genotype carriers (log rank=7.26; P=0.007) and did not present vascular invasion (P=0.03), distant metastasis (P=0.004), or recurrence (P=0.01). MLH1 655A-->G change is associated with an increased risk, although it seems to have a favorable effect on patients, providing a better outcome. Moreover, our results suggest that for genomic profiling to predict the clinical outcome of patients with colorectal cancer, gender must also be considered.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19665066     DOI: 10.1016/j.cancergencyto.2009.04.011

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  10 in total

1.  Intronic and promoter polymorphisms of hMLH1/hMSH2 and colorectal cancer risk in Heilongjiang Province of China.

Authors:  Guangxiao Li; Fulan Hu; Fengshun Yuan; Jialong Fan; Zhifu Yu; Zhiwei Wu; Xiaojuan Zhao; Ye Li; Shuying Li; Jiesheng Rong; Binbin Cui; Xinshu Dong; Huiping Yuan; Yashuang Zhao
Journal:  J Cancer Res Clin Oncol       Date:  2015-01-06       Impact factor: 4.553

2.  The prognostic significance of polymorphisms in hMLH1/hMSH2 for colorectal cancer.

Authors:  Yibaina Wang; Guangxiao Li; Fulan Hu; Haoran Bi; Zhiwei Wu; Xiaojuan Zhao; Ye Li; Shuying Li; Dandan Li; Binbin Cui; Xinshu Dong; Yashuang Zhao
Journal:  Med Oncol       Date:  2014-05-04       Impact factor: 3.064

3.  A modifier of Huntington's disease onset at the MLH1 locus.

Authors:  Jong-Min Lee; Michael J Chao; Denise Harold; Kawther Abu Elneel; Tammy Gillis; Peter Holmans; Lesley Jones; Michael Orth; Richard H Myers; Seung Kwak; Vanessa C Wheeler; Marcy E MacDonald; James F Gusella
Journal:  Hum Mol Genet       Date:  2017-10-01       Impact factor: 6.150

4.  Expression sensitivity analysis of human disease related genes.

Authors:  Liang-Xiao Ma; Ya-Jun Wang; Jing-Fang Wang; Xuan Li; Pei Hao
Journal:  Biomed Res Int       Date:  2013-11-24       Impact factor: 3.411

5.  Polymorphism of MSH2 Gly322Asp and MLH1 -93G>A in non-familial colon cancer - a case-controlled study.

Authors:  Michal Mik; Lukasz Dziki; Katarzyna Malinowska; Radzislaw Trzcinski; Ireneusz Majsterek; Adam Dziki
Journal:  Arch Med Sci       Date:  2017-04-03       Impact factor: 3.318

6.  Pooling-analysis on hMLH1 polymorphisms and cancer risk: evidence based on 31,484 cancer cases and 45,494 cancer-free controls.

Authors:  Sha Li; Yi Zheng; Tian Tian; Meng Wang; Xinghan Liu; Kang Liu; Yajing Zhai; Cong Dai; Yujiao Deng; Shanli Li; Zhijun Dai; Jun Lu
Journal:  Oncotarget       Date:  2017-10-10

Review 7.  DNA repair in cancer initiation, progression, and therapy-a double-edged sword.

Authors:  Katarzyna Kiwerska; Krzysztof Szyfter
Journal:  J Appl Genet       Date:  2019-08-30       Impact factor: 3.240

Review 8.  Do non-pathogenic variants of DNA mismatch repair genes modify neurofibroma load in neurofibromatosis type 1?

Authors:  Anja Harder
Journal:  Childs Nerv Syst       Date:  2022-01-08       Impact factor: 1.475

9.  Micronuclei Formation upon Radioiodine Therapy for Well-Differentiated Thyroid Cancer: The Influence of DNA Repair Genes Variants.

Authors:  Luís S Santos; Octávia M Gil; Susana N Silva; Bruno C Gomes; Teresa C Ferreira; Edward Limbert; José Rueff
Journal:  Genes (Basel)       Date:  2020-09-17       Impact factor: 4.096

Review 10.  DNA Mismatch Repair Gene Variants in Sporadic Solid Cancers.

Authors:  Fabian Caja; Ludmila Vodickova; Jan Kral; Veronika Vymetalkova; Alessio Naccarati; Pavel Vodicka
Journal:  Int J Mol Sci       Date:  2020-08-03       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.